Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L. paracasei NPB01 + L. rhamnosus GG
- Development stage
- Preclinical
- Lead developer
- University of Naples Federico II
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
L. paracasei NPB01 + L. rhamnosus GG is an innovative postbiotic product (iPB) developed through the sequential fermentation of two Lacticaseibacillus species. Unlike live probiotics, this postbiotic consists of non-viable microbial products and metabolic byproducts that exert therapeutic effects without the need for live microorganisms. In preclinical models of breast cancer, including ER+/HER2-, triple-negative (MDA-MB-231), and HER2+ (SKBR3) subtypes, iPB has demonstrated significant antitumor activities. Its mechanism of action involves reducing cancer cell viability and migration, inducing apoptosis, and inhibiting inflammatory cytokine responses. Furthermore, iPB has been shown to upregulate HLA class I surface expression on breast cancer cells, which may enhance their immunogenicity and susceptibility to immune-mediated destruction. The product is being researched by the University of Naples Federico II and the Mayo Clinic for its potential in both the treatment and prevention of breast cancer.
- Other names
- innovative postbiotic productpostbiotic based on sequential fermentation of L. paracasei NPB01 and L. rhamnosus GG
02
Targets
IL10 (Interleukin-10)
Beyond the preview
Go deeper on L. paracasei NPB01 + L. rhamnosus GG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L. paracasei NPB01 + L. rhamnosus GG.